内脏利什曼病药物治疗研究进展

Research development on drug treatment for visceral leishmaniasis

内脏利什曼病在亚洲、非洲，南欧、南美洲80多个国家广泛流行。甲基葡胺五价锑剂和葡萄糖酸锑钠作为治疗各类利什曼病的一线药物，至今已有60多年的历史。本文就内脏利什曼病药物治疗研究进展作扼要综述。

Visceral leishmaniasis （VL） is prevalent in more than 80 countries in Asia, Africa （Leishmania donovani）, southern Europe （L. infantum） and southern America （L.chagasi）. Pentavalent antimonials （Sbv） meglumine antimoniate and sodium stibogluconate （SSG） have been the main first line drug for the treatment of all forms of leishmaniasis since 1940. This article reviews the development on drug treatment for Visceral leishmaniasis.